01901nam a2200337   4500001000800000005001700008007000300025008004100028040000800069041000800077100002700085245008800112300002500200520091700225650003101142650002801173650002201201650001601223650001501239700002401254700001601278700001901294700001501313700002001328700002801348700001801376700002301394700002501417700001801442773010301460ESSALUD20260820161112.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aBhoj, Vijay G. eAutor  aKidney transplantation in two highly sensitized candidates after CAR T-Cell therapy  apáginas: 2117-2125  aHLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.  aENFERMEDAD RENAL CRÓNICA  aTRASPLANTE DE RIÑÓN  aCIRUGÍA GENERAL  aCÉLULAS T  aTRASPLANTE  aKaminski, María    aZhao, Huiwu  aJackson, Kyle   aWang, Wei   aLiu, Chengyang   aMontgomery, Robert A.    aAli, Nicole    aMangiola, Massimo   aSpitzer, Thomas R.    aSafa, Kassem 0 022717dMassachusetts NEJM GroupoNEJM011tThe New England Journal of Medicine wESSALUDx0028-4793